Navigation Links
Sunesis Pharmaceuticals Receives NASDAQ Notification
Date:4/17/2009

timeline to achieve and sustain compliance. The Company intends to submit in a timely manner to the NASDAQ Staff a plan to continue listing on The NASDAQ Global Market. There is no assurance that NASDAQ will accept the Company's plan to satisfy the stockholders' equity requirement.

If, after the completion of its review, NASDAQ determines that the Company has not presented a plan that adequately addresses the stockholders' equity issue, NASDAQ will provide written notice that the Company's securities will be subject to delisting from The NASDAQ Global Market. In that event, the Company may either apply for listing on The NASDAQ Capital Market, provided it meets the continued listing requirements of that market, or appeal the decision to a NASDAQ Listing Qualifications Panel. In the event of an appeal, the Company's securities would remain listed on The NASDAQ Global Market pending a decision by the Panel following the hearing.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

This press release contains forward-looking statements, including, without limitation, statements related to the timeliness of the Company's submission of a compliance plan to NASDAQ, the continued listing of the Company's common stock on The NASDAQ Global Market, the amount of the Company's stockholders' equity as of any future date, the basis upon which NASDAQ may grant an ex
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
2. Sunesis to Present at the 11th Annual BIO CEO & Investor Conference
3. Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
4. Sunesis to Present at Upcoming Conferences
5. Sunesis to Present at Upcoming Conferences
6. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
7. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
8. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
9. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
11. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2014)... PARSIPPANY, N.J. , Aug. 31, 2014 ... New Drug Discovery program in Anti-Infective research when two ... the coveted Qualified Infectious Disease Product (QIDP) status from ... granted to drugs which act against pathogens which have ... and are identified by Centre for Disease Control (a ...
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... VANCOUVER , Aug. 29, 2014 /PRNewswire/ - ... (OTCQX: ICOTF), today reported financial results for the ... specified otherwise, are expressed in Canadian dollars and ... Second Quarter 2014 Highlights , ... visual acuity (VA) primary endpoint for subjects enrolled ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
Breaking Biology Technology:U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2
... 16 The landscape of scientific,publications strategy, planning ... guidelines. Half of global publications groups are fully,located ... a shift,to medical groups to increase clinical presentation, ... LLC., In a benchmarking study that included ...
... of international, multi-center registry presented at conference, ... BSX ) today announced that results from ... clinical utility,of the SpyGlass(R) Direct Visualization System will ... from May 17-22 in San Diego,CA. Registry results ...
... Products, L.P. Sponsors Program to Recognize Exemplary Work ... ... 16 CURE magazine announced the winner,and finalists of its ... the Oncology Nursing Society,s (ONS) 33rd Annual,Congress. Ortho Biotech Products, ...
Cached Biology Technology:Industry Executives Finding Value in Shift of Scientific Publications 2Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 2Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 3Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 4Boston Scientific's SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R) 5CURE Magazine Announces Winner of 2008 Extraordinary Healer Award 2
(Date:9/2/2014)... in stride; others are done in by it. New ... of this so-called stress gap in mice with very ... researchers to better understand the development of psychiatric disorders ... animal has unique experiences as it goes through its ... alter the expression of genes, and as a result, ...
(Date:9/1/2014)... diet showed some modest improvement in the last decade ... consumption of unhealthy trans fats, but the gap in ... poor. , , An unhealthy diet is closely linked ... healthy diet is an important part of the strategy ... diet quality is important because it can offer guidance ...
(Date:9/1/2014)... It may be possible to train the brain to ... to new research by scientists at the Jean Mayer ... at Tufts University and at Massachusetts General Hospital. Published ... , a brain scan study in adult men and ... addictive power of unhealthy food while also increasing preference ...
Breaking Biology News(10 mins):Discovery hints at why stress is more devastating for some 2Discovery hints at why stress is more devastating for some 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3Training your brain to prefer healthy foods 2
... Philadelphia have manipulated cell activity that occurs during the ... in animal studies. The finding has the potential to ... since already existing drugs might be pressed into service ... or ischemia, is a major problem in many organs, ...
... reigned supreme on the Earth, thriving by filling every ... before humans first arrived on the scene. Now, ... infinite variety of food sources may play a significant ... crisis, according to the Biodesign Institute,s Bruce Rittmann, Rosa ...
... significant step closer to climbing into the driver,s seat of ... School of Medicine in St. Louis report in Nature ... HS1, enables key functions of natural killer (NK) cells, which ... allows the NK cells to pursue their targets, latch on ...
Cached Biology News:Novel approach may protect against heart attack injury 2Can microorganisms be a solution to the world's energy problems? 2Can microorganisms be a solution to the world's energy problems? 3Can microorganisms be a solution to the world's energy problems? 4Control switches found for immune cells that fight cancer, viral infection 2